Regulation on clinical trials - Comment of the European LeukemiaNet

In the last newsletter, we reported on the draft regulation on clinical trials and the alarming suggestions presented in the rapport from different Committees of the European Parliament. At the beginning of April, a comment of the European LeukemiaNet by Nicola Gökbüget was sent to the rapporteurs. The comment is available to be viewed online.  ▶ ELN comment on draft regulation

Update of WP participants

On a half-yearly basis the contact data of active WP participants are updated on the website. The current lists as well as short overviews of the respective lead participants are online now. Please find these lists including the participant’s organization, nationality and e-mail address in the section “contact” of every workpackage. ▶ contact NMC for changes

Publications from the Network (selected)

Acute lymphoblastic leukemia


Acute myeloid leukemia

- Bacher U et al. Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. Leuk Lymphoma. 2013 Mar;54(3):639-42.
- Fasan A et al. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. Leukemia. 2013 Feb;27(2):482-5.

**Chronic myeloid leukemia**

**Chronic lymphocytic leukemia**

**Chronic myeloproliferative diseases**

**Myelodysplastic syndromes**
- Bacher U et al. Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups. Leuk Lymphoma. 2013 Mar;54(3):639-42.
- van de Loosdrecht AA et al. Rationale for the clinical application of flow cytometry in patients with

Diagnostics

Miscellaneous
- Clark T et al. Sample size determinations in original research protocols for randomised clinical trials submitted to UK research ethics committees: review. BMJ. 2013 Mar 21;346:f1135.

New trials in the ELTR

**ENESTFreedom** A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment

**EPIC** A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase